Grifols, the Spanish company that recently completed its acquisition of Talecris Biotherapeutics, announced today a new board of directors for its U.S. operations.

Gregory Rich, who has served as CEO of Grifols U.S. operations since 2003, will oversee Talecris' operations in the Triangle, which include a massive blood plasma plant in Clayton and corporate offices in Research Triangle Park.

Thomas Glanzmann was named chairman of the U.S. board. He will also oversee the integration of Talecris into Grifols.

Glanzmann was previously president and CEO of Gambro, which manufactures and supplies products and therapies for kidney and liver dialysis, and other therapies.

He stepped down as CEO earlier this year.
 

Talecris Biotherapeutics has lost a legal fight over its contract dispute with Plasma Centers of America.

The Research Triangle Park company announced this morning that a Wake County jury on Monday ordered Talecris to pay $37 million to its former partner. Talecris is considering its response, including a possible appeal.